144 related articles for article (PubMed ID: 38085652)
1. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
Margot N; Pennetzdorfer N; Naik V; Rhee M; Callebaut C
Antivir Ther; 2023 Dec; 28(6):13596535231220754. PubMed ID: 38085652
[TBL] [Abstract][Full Text] [Related]
2. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
Margot NA; Naik V; VanderVeen L; Anoshchenko O; Singh R; Dvory-Sobol H; Rhee MS; Callebaut C
J Infect Dis; 2022 Nov; 226(11):1985-1991. PubMed ID: 36082606
[TBL] [Abstract][Full Text] [Related]
3. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
Chatzidaki I; Curteis T; Luedke H; Mezzio DJ; Rhee MS; McArthur E; Eddowes LA
Value Health; 2023 Jun; 26(6):810-822. PubMed ID: 36566886
[TBL] [Abstract][Full Text] [Related]
4. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.
Margot N; Ram R; Rhee M; Callebaut C
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288639
[TBL] [Abstract][Full Text] [Related]
5. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
Lee NE; Sutherland RK
Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
[TBL] [Abstract][Full Text] [Related]
7. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
[TBL] [Abstract][Full Text] [Related]
8. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
10. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.
Toma J; Weinheimer SP; Stawiski E; Whitcomb JM; Lewis ST; Petropoulos CJ; Huang W
J Virol; 2011 Apr; 85(8):3872-80. PubMed ID: 21289125
[TBL] [Abstract][Full Text] [Related]
11. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
[TBL] [Abstract][Full Text] [Related]
12. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
[TBL] [Abstract][Full Text] [Related]
13. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
14. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
[TBL] [Abstract][Full Text] [Related]
15. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
[TBL] [Abstract][Full Text] [Related]
16. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
Prather C; Lee A; Yen C
Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
[TBL] [Abstract][Full Text] [Related]
18. No antagonism or cross-resistance and a high barrier to the emergence of resistance
Diamond TL; Goh SL; Ngo W; Rodriguez S; Xu M; Klein DJ; Grobler JA; Asante-Appiah E
Antimicrob Agents Chemother; 2024 Jun; ():e0033424. PubMed ID: 38864613
[TBL] [Abstract][Full Text] [Related]
19. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
20. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
